4-Fluorophenibut (developmental code name CGP-11130; also known as β-(4-fluorophenyl)-γ-aminobutyric acid or β-(4-fluorophenyl)-GABA) is a GABAB receptoragonist which was never marketed.[1] It is selective for the GABAB receptor over the GABAA receptor (IC50 = 1.70μM and > 100μM, respectively).[1] The drug is a GABA analogue and is closely related to baclofen (β-(4-chlorophenyl)-GABA), tolibut (β-(4-methylphenyl)-GABA), and phenibut (β-phenyl-GABA).[1] It is less potent as a GABAB receptor agonist than baclofen but more potent than phenibut.[1]
The substance is sometimes referred to as 4F-phenibut, F-phenibut, or baflofen, and colloquially as fluorobut.
Legal status
F-Phenibut is a prohibited substance in Lithuania[2] and Hungary.[3]
